Current status of thalidomide and its role in the treatment of metastatic prostate cancer (Q35173059)

6 August 2017

1 reference

title

Current status of thalidomide and its role in the treatment of metastatic prostate cancer (English)

1 reference

6 August 2017

0 references

1 reference

Gordon R Macpherson

1

1 reference

6 August 2017

Michael Franks

2

1 reference

6 August 2017

Andrada Tomoaia-Cotisel

3

1 reference

6 August 2017

Yuichi Ando

4

1 reference

6 August 2017

Douglas K Price

5

1 reference

6 August 2017

William D Figg

6

1 reference

6 August 2017

language of work or name

1 reference

1 June 2003

1 reference

Critical Reviews in Oncology Hematology

6 August 2017

published in

1 reference

6 August 2017

volume

46 Suppl

1 reference

6 August 2017

page(s)

S49-57

1 reference

Thalidomide: a novel template for anticancer drugs

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Synthesis and immunological activity of water-soluble thalidomide prodrugs

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

THALIDOMIDE AND CONGENITAL ABNORMALITIES

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

THALIDOMIDE IN THE TREATMENT OF LEPRA REACTIONS

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Thalidomide for the treatment of chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Thalidomide inhibits the replication of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Current role of thalidomide in cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Induction of angiogenesis during the transition from hyperplasia to neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Thalidomide in cancer: potential uses and limitations

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Thalidomide in the treatment of relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Activity of thalidomide in AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Thalidomide in solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

The treatment of advanced renal cell cancer with high-dose oral thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: A morphometric study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Microvascularity in benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Microvessel density in core biopsies of prostatic adenocarcinoma: a stage predictor?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Vascular density is a predictor of cancer-specific survival in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Assessment of the vascularization in prostatic carcinoma: a morphometric investigation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: lack of significance for microvessel density analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

8:45-9:00. Using PET 18F-FDG, 11CO, and 15O-water for Monitoring Prostate Cancer During a Phase II Anti-angiogenic Drug Trial with Thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Teratogen metabolism: spontaneous decay products of thalidomide and thalidomide analogues are not bioactivated by liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Induction of morphological differentiation in the human leukemic cell line K562 by exposure to thalidomide metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human skin fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Evaluation of the developmental toxicity of thalidomide using frog embryo teratogenesis assay-xenopus (FETAX): biotransformation and detoxification.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Hydroxylated metabolites of thalidomide: formation in-vitro and in-vivo in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Factors promoting tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

The revitalization of thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Hypothesis: thalidomide embryopathy-proposed mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Mechanism of action in thalidomide teratogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

The role of cyclooxygenase-2 in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Enantioselective inhibition of TNF-alpha release by thalidomide and thalidomide-analogues

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

A double-blind study of the sedative effects of the thalidomide enantiomers in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900064-7

7 January 2021

10.1016/S1040-8428(03)00064-7

Identifiers

DOI

1 reference

6 August 2017

1 reference